One-Step Biallelic and Scarless Correction of a β-Thalassemia Mutation in Patient-Specific iPSCs without Drug Selection
Open Access
- 1 March 2017
- journal article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 6, 57-67
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81570101, 81370766, 31601187, 81671121, 81401254)
- Bureau of Education of Guangzhou Municipality (201505011111498)
- New York University
- Science and Technology Planning Project of Guangdong Province (2016A020216023, 2014TQ01R683, 2015A030310119, 2014A02011029)
This publication has 23 references indexed in Scilit:
- Genetically humanized pigs exclusively expressing human insulin are generated through custom endonuclease-mediated seamless engineeringJournal of Molecular Cell Biology, 2016
- ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotesNature Communications, 2016
- High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effectsNature, 2016
- Recent trends in the gene therapy of β-thalassemiaJournal of Blood Medicine, 2015
- Small Molecules Enhance CRISPR Genome Editing in Pluripotent Stem CellsCell Stem Cell, 2015
- Optimization of scarless human stem cell genome editingNucleic Acids Research, 2013
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Advances in the allogeneic transplantation for thalassemiaBlood Reviews, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- β-ThalassemiaNew England Journal of Medicine, 2005